Inhibrx Biosciences, Inc. (INBX) — Cash Flow-to-Debt Ratio
Inhibrx Biosciences, Inc. (INBX) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2025, meaning its operating cash flow of $-30.12 Million could theoretically repay 0% of its total liabilities ($138.49 Million) in one year. See working capital position of Inhibrx Biosciences, Inc. to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Inhibrx Biosciences, Inc. Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Inhibrx Biosciences, Inc. across 10 annual periods. Also explore Inhibrx Biosciences, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Inhibrx Biosciences, Inc. (2016–2025)
Year-by-year debt coverage analysis for Inhibrx Biosciences, Inc.. For market capitalisation and broader financial context, see Inhibrx Biosciences, Inc. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | $-129.79 Million | $138.49 Million | ▲ +77.3% |
| 2024 | -4.12x | $-194.41 Million | $47.18 Million | ▼ -463.5% |
| 2023 | -0.73x | $-193.31 Million | $264.39 Million | ▼ -47.6% |
| 2022 | -0.50x | $-115.30 Million | $232.82 Million | ▲ +39.5% |
| 2021 | -0.82x | $-80.32 Million | $98.07 Million | ▼ -16.6% |
| 2020 | -0.70x | $-47.97 Million | $68.27 Million | ▼ -163.0% |
| 2019 | -0.27x | $-32.08 Million | $120.06 Million | ▲ +21.7% |
| 2018 | -0.34x | $-23.09 Million | $67.63 Million | ▲ +27.8% |
| 2017 | -0.47x | $-18.75 Million | $39.67 Million | ▲ +47.7% |
| 2016 | -0.90x | $-18.11 Million | $20.03 Million | — |